Email Updates

Search form

You are here

12 APRIL 2019 VOLUME 20 ISSUE 14

Media Coverage

  • This year, the World Health Organization named vaccine hesitancy as one of the top 10 global health threats, alongside threats as grave as climate change, antimicrobial resistance, Ebola virus, and the next influenza pandemic. What happened? How did vaccine reluctance and refusal become such a major risk?

    April 12, 2019
    General
    Science Magazine
  • Vice President Yemi Osinbajo has said that Nigeria is making steady progress in improving access to HIV/AIDS services through increased number of facilities offering such services in the country.

    April 12, 2019
    Guardian Nigeria
  • Despite recent research revealing that antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) both greatly reduce the chances of HIV transmission, the “Undetectable Equals Untransmittable” message is not being promoted by all providers who work with HIV patients or those at risk of HIV.

    April 12, 2019
    Contagion Live
  • Black men who have sex with men (MSM) in London experience a unique set of motivations and barriers to using pre-exposure prophylaxis (PrEP), according to the results of a recent qualitative study published in Sexually Transmitted Infections. This research was carried out by T. Charles Witzel and colleagues at the London School of Hygiene and Tropical Medicine.

    April 12, 2019
    aidsmap
  • The Cuban government last month began to distribute PrEP through a pilot program in the city of Cárdenas. The program comes less than 30 years after the Cuban government forcibly quarantined people with HIV/AIDS in state-run sanitaria.

    April 11, 2019
    Washington Blade
  • At least 50 percent of sex workers in Zimbabwe are carrying the HIV virus, a United Nations report has revealed.

    April 11, 2019
    General
    All Africa
  • An Australian man recently made headlines as the seventh reported case, worldwide, of a failure of PrEP (Pre-Exposure Prophylaxis), the groundbreaking drug regimen shown to be 99 percent effective at preventing HIV infection with daily adherence. While understandably disconcerting for users, PrEP failures are major news because they are so rare—and Truvada (tenofovir disoproxil fumarate/emtricitabine), the drug used for PrEP, is unquestionably one of the best tools we have for stopping the spread of HIV.

    April 10, 2019
    Slate
  • Amid ongoing efforts to thwart HIV, AIDS activists are growing increasingly frustrated with the Centers for Disease Control and Prevention for failing to reach a deal with Gilead Sciences (GILD) over royalties on its sales of the Truvada prevention pill. Although the agency has refused to publicly discuss the subject, the activists hope any funds that could become available will be used for combating the virus.

    April 10, 2019
    STAT
  • One of the many mysteries that scientists working with HIV have been trying to solve is how the virus keeps its identity hidden in the body. The virus can be detected in blood, but once it gains entry into our cells, it remains obscure and out of reach of the immune system. And this inability to detect the virus in our cells has hindered efforts to properly eliminate the disease.

    April 10, 2019
    Antibody Related Research
    STAT
  • A Yale-led team has discovered yet another molecular trick HIV uses to survive immune system attacks, a finding that may influence efforts to develop an effective vaccine against HIV/AIDS.

    April 10, 2019
    Yale News
  • The HIV-1 envelope protein is the target of antibodies that neutralize the virus. A fresh look into the conformational states of this protein relaunches the quest to identify those relevant for vaccine design.

    April 10, 2019
    Nature
  • The HIV and sexually transmitted infection (STI) epidemics, which have always been and will always be intertwined, are at an inflection point. Two scientific advancements over the last decade have substantially influenced the sexual health of people living with HIV and individuals at risk for HIV.

    April 9, 2019
    JAMA
  • Giving men who have sex with men (MSM) access to free self-screening HIV kits would increase testing among hard-to-reach groups and help South Africa reach its HIV targets.

    April 8, 2019
    General
    Times Live
  • Disgusted by Big Pharma greed? Furious at the fact that Gilead charges $2,000 a month for Truvada if insurance doesn’t cover it? Good news! A new daily PrEP alternative might be hitting the market soon, and — oh wait, it’s also made by Gilead and it will also probably cost $2,000 a month out of pocket.

    April 8, 2019
    OUT
  • Health Minister Aaron Motsoaledi says the government will send a team to the US following an announcement that Washington plans to cut funding for HIV/AIDS treatment programmes. Motsoaledi said that the announcement is not final at this stage. South Africa has the biggest HIV/AIDS treatment plan in the world.

    April 8, 2019
    General
    Eyewitness News

Published Research

Announcements